These in vivo observations were confirmed by in vitro experiments with immortalized ovarian cancer cell lines OVCAR8 and SKOV3, as well as paclitaxel resistant derivatives of these lines [44] and echoes many recent reports that suggest HDAC inhibition can potentiate conventional and targeted therapeutics. This evidence concerns the gene HDAC9 and ovarian cancer.